inflammation and glp 1 Frontiers Incretins as Multi–Disease State Treatments
Description
Projected global sales by 2030 for GLP-1 could increase by 2.6x
AstraZenecas deep pipeline of medicines focusing on their key therapeutic areas.
Protect efficacy, meet regulations, and build patient trust.
Viking Therapeutics stock more than doubled on Tuesday following the release of trials results suggesting its injectable obesity treatment outperforms industry leaders like Novo Nordisks Wegovy and Eli Lillys Zepbound.
start
